Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SI | P14410 | 2/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7456831 | 0.82 | PSMB8 (0.53) | PARP1CHEK1PSMB8MGAMGAA | |
| SCHEMBL10285823 | 0.82 | MGAM (0.50) | PARP1MGAMGAASIMGAM2 | |
| SCHEMBL14765025 | 0.79 | MGAM (0.45) | PARP1MGAMGAASIMGAM2 | |
| SCHEMBL14765083 | 0.79 | BRD4 (0.40) | PARP1CHEK1DAOPDGFRBFGFR1 | |
| SCHEMBL30196961 | 0.79 | MGAM (0.45) | PARP1MGAMGAASIMGAM2 | |
| SCHEMBL3237187 | 0.79 | PARP1 (0.53) | PARP1MGAMGAASIMGAM2 | |
| SCHEMBL29657549 | 0.79 | PSMB8 (0.46) | PARP1CHEK1PSMB8MGAMGAA | |
| SCHEMBL4173826 | 0.79 | PSMB8 (0.46) | PARP1CHEK1PSMB8MGAMGAA | |
| SCHEMBL8265192 | 0.78 | PARP1 (0.59) | PARP1CHEK1PSMB8MGAMGAA | |
| SCHEMBL10252257 | 0.77 | PARP1 (0.45) | PARP1GAASMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2352725-A1 | QUINOXALINE-BASED LXR MODULATORS | Wyeth LLC (US) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010054229-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH LLC (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PARP1 857/4885CHEK1 881/4885PSMB8 491/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PARP1 857/4885CHEK1 881/4885PSMB8 491/4885 |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PARP1 857/4885CHEK1 881/4885PSMB8 491/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PARP1 857/4885CHEK1 881/4885PSMB8 491/4885 |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | PARP1 4063/4885CHEK1 2577/4885PSMB8 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.